Newsroom

OnQuality Pharmaceuticals Expands Part 2 of the NOVA-II Phase 2 Clinical Trial to China and India

View on PR Newswire SEATTLE, Jan. 5, 2023 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive therapy...

Targeted Oncology First Patient With VEGFRi-Associated Hand-Foot Skin Reaction Enrolled in NOVA-II

Jordyn Sava November 10, 2022 Part 2 of the NOVA-II phase 2 trial evaluating OQL011 has enrolled the first patient with cancer with...

Clinical Trials Arena I OnQuality enrols first subject in Phase II HFSR therapy trial

November 9, 2022 The key objectives include the assessment of the efficacy and safety of OQL011 and the identification of an optimal...

OnQuality Pharmaceuticals Announces Enrollment of First Patient in Part 2 of the NOVA-II Phase 2

View on PR Newswire SEATTLE, Nov. 8, 2022 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive...

OnQuality Pharmaceuticals to Present Two Posters at the 34th EORTC-NCI-AACR Symposium

Preclinical toxicology and pharmacology data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic...

Behind Biotech I Hong Tang on Traditional Chinese Medicine and Targeted Cancer Supportive Therapy

Hosted by Jingyi Liu August 3, 2022 Hong Tang Biography Dr. Hong Tang is Chief Medical Officer, and co-founder of OnQuality...

Hopkins Biotech Podcast I Hong Tang: Targeting the Common Side Effects of Cancer Therapies

Hosted by Joe Varriale June 30, 2022 Hong Tang is the co-founder and Chief Medical Officer of OnQuality Pharmaceuticals, a targeted...

Fierce Biotech I After 3 years away, BIO marked by first-time handshakes

Written by Max Bayer June 15, 2022 Six days after the World Health Organization officially declared COVID-19 a global pandemic on March...

BioSpectrum Asia I Our approach to managing the side effects of cancer therapy has evolved

Source: https://www.biospectrumasia.com/e-magazine By Dr. Manbeena Chawla June 2022 Although there has been tremendous progress in...

OnQuality Pharmaceuticals to Have Two Abstracts Published in the 2022 ASCO Annual Meeting Proceeding

View on PRNewswire - Preclinical data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic treatment for...